11:30 AM EST - Knight Therapeutics Inc. : Announced today the launch of TAVALISSE® (fostamatinib disodium hexahydrate) in Brazil, for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Knight Therapeutics Inc.
shares T.GUD are trading up $0.12 at $10.48.
